- Home
- OPT vs SCWX Comparison
OPT vs SCWX Comparison
Compare OPT & SCWX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- SCWX
- Stock Information
- Founded
- OPT 1984
- SCWX 1999
- Country
- OPT Australia
- SCWX United States
- Employees
- OPT N/A
- SCWX N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- SCWX Computer Software: Prepackaged Software
- Sector
- OPT Health Care
- SCWX Technology
- Exchange
- OPT Nasdaq
- SCWX Nasdaq
- Market Cap
- OPT 767.9M
- SCWX 744.0M
- IPO Year
- OPT 2020
- SCWX 2016
- Fundamental
- Price
- OPT $3.24
- SCWX $8.37
- Analyst Decision
- OPT Strong Buy
- SCWX Sell
- Analyst Count
- OPT 1
- SCWX 2
- Target Price
- OPT $12.00
- SCWX $7.00
- AVG Volume (30 Days)
- OPT 39.0K
- SCWX 428.9K
- Earning Date
- OPT 08-30-2024
- SCWX 12-05-2024
- Dividend Yield
- OPT N/A
- SCWX N/A
- EPS Growth
- OPT N/A
- SCWX N/A
- EPS
- OPT N/A
- SCWX N/A
- Revenue
- OPT $261,859.00
- SCWX $346,352,000.00
- Revenue This Year
- OPT N/A
- SCWX N/A
- Revenue Next Year
- OPT $46,864.64
- SCWX $4.26
- P/E Ratio
- OPT N/A
- SCWX N/A
- Revenue Growth
- OPT N/A
- SCWX N/A
- 52 Week Low
- OPT $1.79
- SCWX $5.61
- 52 Week High
- OPT $5.45
- SCWX $9.76
- Technical
- Relative Strength Index (RSI)
- OPT 27.29
- SCWX 55.54
- Support Level
- OPT $4.02
- SCWX $8.35
- Resistance Level
- OPT $4.18
- SCWX $8.40
- Average True Range (ATR)
- OPT 0.22
- SCWX 0.02
- MACD
- OPT -0.13
- SCWX -0.02
- Stochastic Oscillator
- OPT 6.85
- SCWX 50.00
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About SCWX SecureWorks Corp.
SecureWorks Corp is a cybersecurity provider of technology-driven solutions singularly focused on protecting its customers by outpacing and outmaneuvering the adversary. The company offers its customers the following services; software-as-a-service, or SaaS, solutions, managed solutions, and professional services, including incident response and adversarial services. Its solutions enable organizations to fortify their cyber defenses to prevent security breaches, detect malicious activity in real-time, prioritize and respond to security incidents, and predict emerging threats. The company's products consist of MDR, XDR, Threat Hunting, Log Management, NGAV, EDR, IDPS.